TEVA - Teva Pharmaceutical Industries Ltd Stock Price, Fair Value and News

16.25USD+0.25 (+1.56%)Market Closed

Market Summary

USD16.25+0.25

Market Closed

1.56%

TEVA Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

TEVA Stock Price

View Fullscreen

TEVA RSI Chart

TEVA Valuation

Market Cap

18.1B

Price/Earnings (Trailing)

-36.67

Price/Sales (Trailing)

1.13

EV/EBITDA

11.11

Price/Free Cashflow

13.06

TEVA Price/Sales (Trailing)

TEVA Profitability

EBT Margin

-5.22%

Return on Equity

-6.56%

Return on Assets

-1.16%

Free Cashflow Yield

7.66%

TEVA Fundamentals

TEVA Revenue

Revenue (TTM)

16.0B

Rev. Growth (Yr)

4.32%

Rev. Growth (Qtr)

-14.31%

TEVA Earnings

Earnings (TTM)

-494.5M

Earnings Growth (Yr)

36.82%

Earnings Growth (Qtr)

-131.2%

Breaking Down TEVA Revenue

52 Week Range

7.0916.55

(Low)(High)

Last 7 days

13.7%

Last 30 days

14.6%

Last 90 days

33.3%

Trailing 12 Months

91.7%

How does TEVA drawdown profile look like?

TEVA Financial Health

Current Ratio

0.89

TEVA Investor Care

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.0B	0	0	0
2023	14.9B	15.0B	15.3B	15.8B
2022	15.6B	15.4B	15.1B	14.9B
2021	16.3B	16.3B	16.2B	15.9B
2020	17.1B	16.8B	16.7B	16.7B
2019	17.5B	17.1B	16.8B	16.9B
2018	21.7B	20.5B	19.3B	18.3B
2017	22.7B	23.4B	23.5B	22.4B
2016	19.5B	19.6B	20.3B	21.9B
2015	20.3B	20.2B	19.9B	19.7B
2014	20.4B	20.5B	20.5B	20.3B
2013	20.2B	20.1B	20.2B	20.3B
2012	19.2B	20.0B	20.6B	20.3B
2011	16.5B	17.0B	17.1B	18.3B
2010	16.6B	17.0B	17.7B	16.1B
2009	11.7B	12.2B	12.9B	16.1B
2008	9.8B	10.2B	10.7B	11.1B
2007	0	0	0	9.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Teva Pharmaceutical Industries Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	kalif eliyahu sharon	sold	-1,048,120	13.5154	-77,550	evp, chief financial officer
Mar 05, 2024	daniell richard	acquired	-	-	77,802	exec. vp, european commercial
Mar 05, 2024	conway vikki l	acquired	-	-	4,954	see remarks
Mar 05, 2024	weiss amir	acquired	-	-	3,564	chief accounting officer
Mar 05, 2024	kalif eliyahu sharon	acquired	-	-	73,707	evp, chief financial officer
Mar 05, 2024	drape eric	acquired	-	-	77,802	executive vp global operations
Mar 05, 2024	sabag mark	sold	-1,352,090	13.5209	-100,000	evp, international markets
Mar 05, 2024	conway vikki l	sold	-19,286	13.5154	-1,427	see remarks
Mar 05, 2024	daniell richard	sold	-657,240	13.5154	-48,629	exec. vp, european commercial
Mar 05, 2024	sabag mark	acquired	-	-	81,897	evp, international markets

Which funds bought or sold TEVA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	US BANCORP \DE\	added	113	75,596	115,560	-%
May 08, 2024	PRIVATE MANAGEMENT GROUP INC	reduced	-3.23	4,876,390	20,718,400	0.78%
May 08, 2024	Bell Investment Advisors, Inc	added	23.57	1,098	2,738	-%
May 08, 2024	EDMOND DE ROTHSCHILD HOLDING S.A.	added	4.02	99,783	345,624	0.01%
May 08, 2024	TD Asset Management Inc	reduced	-2.2	764,331	3,139,310	-%
May 08, 2024	COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS	added	0.5	668,994	2,535,950	0.02%
May 08, 2024	KBC Group NV	added	70.57	207,000	366,000	-%
May 08, 2024	EMERALD MUTUAL FUND ADVISERS TRUST	new	-	154,420	154,420	0.01%
May 08, 2024	Focused Wealth Management, Inc	sold off	-100	-37,213	-	-%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	added	13.41	-22,032	548,859	-%

Are Funds Buying or Selling TEVA?

Are funds buying TEVA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TEVA

No. of Funds

Unveiling Teva Pharmaceutical Industries Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	phoenix holdings ltd.	4.83%	54,144,997	SC 13G/A
Feb 01, 2024	phoenix holdings ltd.	5.40%	60,522,178	SC 13G
Jun 09, 2023	capital research global investors	0.0%	0	SC 13G/A
Feb 13, 2023	capital research global investors	10.3%	114,793,989	SC 13G/A
Feb 11, 2022	capital research global investors	12.0%	132,350,750	SC 13G/A
Feb 16, 2021	capital research global investors	11.9%	130,140,247	SC 13G/A
Feb 03, 2021	wellington management group llp	0.03%	310,793	SC 13G/A
Feb 14, 2020	capital research global investors	11.9%	130,950,677	SC 13G/A
Feb 05, 2020	franklin resources inc	1.8%	19,916,016	SC 13G/A
Jan 28, 2020	wellington management group llp	7.43%	81,123,996	SC 13G

Recent SEC filings of Teva Pharmaceutical Industries Ltd

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	ARS	ARS
Apr 16, 2024	DEF 14A	DEF 14A
Apr 16, 2024	DEFA14A	DEFA14A
Apr 09, 2024	SC 13G/A	Major Ownership Report
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading

Peers (Alternatives to Teva Pharmaceutical Industries Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	360.8B	85.6B	-1.57%	-7.27%	9.38	4.21	5.68%	202.39%
MRK	329.8B	61.4B	2.75%	10.43%	143.01	5.37	6.11%	-82.30%
AMGN	167.8B	29.5B	15.72%	33.63%	44.6	5.68	12.76%	-52.47%
PFE	159.7B	57.8B	5.27%	-25.60%	127.44	2.76	76.51%	-86.81%
GILD	80.5B	27.4B	-7.64%	-17.30%	166.11	2.93	1.51%	-91.32%
TEVA	18.1B	16.0B	14.60%	91.74%	-36.67	1.13	7.23%	71.10%
MID-CAP
PRGO	4.2B	4.6B	-3.76%	-14.95%	-549.18	0.93	-0.06%	94.55%
ALKS	4.1B	1.7B	-9.20%	-22.63%	9.45	2.38	54.01%	364.56%
BHC	2.5B	9.0B	-24.84%	16.97%	-5.6	0.28	10.01%	-27.45%
AMPH	2.0B	644.4M	3.79%	3.06%	14.84	3.17	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-4.37%	-28.36%	-4.33	2.05	24.65%	80.36%
TXMD	23.4M	1.3M	-5.58%	-47.55%	-2.28	17.98	-98.14%	-109.18%
ACRX	17.3M	-	-14.29%	43.16%	-0.94	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	5.41%	-93.33%	-0.17	0.13	80.00%	43.08%
ACOR	807.4K	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Teva Pharmaceutical Industries Ltd News

Latest updates

Teva Pharmaceutical Industries Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-14.3%	3,819,000,000	4,457,000,000	3,850,000,000	3,878,000,000	3,661,000,000	3,883,500,000	3,595,000,000	3,786,000,000	3,661,000,000	4,099,500,000	3,887,000,000	3,910,000,000	3,982,000,000	4,454,000,000	3,978,000,000	3,870,000,000	4,357,000,000	4,468,000,000	4,093,000,000	4,177,000,000	4,149,000,000
Gross Profit	-26.7%	1,771,000,000	2,415,500,000	1,851,000,000	1,796,000,000	1,582,000,000	1,770,000,000	1,669,000,000	1,794,000,000	1,740,000,000	2,049,500,000	1,794,000,000	1,873,000,000	1,878,000,000	2,048,000,000	1,852,000,000	1,763,000,000	2,063,000,000	1,958,000,000	1,830,000,000	1,893,000,000	1,856,000,000
S&GA Expenses	-0.4%	608,000,000	610,500,000	576,000,000	603,000,000	546,000,000	548,500,000	539,000,000	594,000,000	584,000,000	631,500,000	597,000,000	615,000,000	585,000,000	683,000,000	605,000,000	597,000,000	613,000,000	705,500,000	595,000,000	666,000,000	648,000,000
EBITDA Margin	-15.1%	0.09	0.10	-0.01	0.00	-0.02	-0.06	0.01	0.02	0.11	0.18	0.20	-0.10	-0.11	-0.12	-0.13	0.12	0.08	0.08	-0.13	-0.12	-0.08
Income Taxes	-228.4%	-52,000,000	40,500,000	-12,000,000	-16,000,000	-19,000,000	149,000,000	107,000,000	-900,000,000	2,000,000	-24,500,000	76,000,000	98,000,000	62,000,000	-21,000,000	16,000,000	-104,000,000	-59,000,000	-119,000,000	11,000,000	-179,000,000	9,000,000
Earnings Before Taxes	-195.3%	-467,000,000	490,000,000	64,000,000	-923,000,000	-272,000,000	-1,185,000,000	171,000,000	-1,178,000,000	-971,000,000	-175,500,000	382,000,000	308,000,000	144,000,000	137,000,000	-4,459,000,000	-51,000,000	-33,000,000	-39,000,000	-292,000,000	-850,000,000	-84,000,000
EBT Margin	-29.1%	-0.05	-0.04	-0.15	-0.15	-0.17	-0.21	-0.14	-0.13	-0.03	0.04	0.06	-0.24	-0.26	-0.26	-0.27	-0.02	-0.07	-0.07	-0.27	-0.26	-0.22
Net Income	-131.2%	-139,000,000	445,500,000	70,000,000	-871,000,000	-220,000,000	-1,301,000,000	61,000,000	-251,000,000	-955,000,000	-159,000,000	292,000,000	207,000,000	77,000,000	150,000,000	-4,349,000,000	140,000,000	69,000,000	110,000,000	-314,000,000	-689,000,000	-105,000,000
Net Income Margin	14.9%	-0.03	-0.04	-0.15	-0.16	-0.11	-0.16	-0.09	-0.07	-0.04	0.03	0.04	-0.24	-0.24	-0.24	-0.24	0.00	-0.05	-0.06	-0.24	-0.23	-0.19
Free Cashflow	-122.8%	-243,000,000	1,065,000,000	-114,000,000	205,000,000	-284,000,000	831,000,000	421,000,000	-4,000,000	-206,000,000	303,000,000	383,000,000	105,000,000	-555,000,000	155,000,000	164,000,000	142,000,000	177,000,000	419,000,000	156,000,000	-339,000,000	-13,000,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.6%	42,773	43,479	42,095	43,100	43,461	44,011	44,252	45,932	47,059	47,666	47,851	49,195	49,004	50,640	49,737	54,991	55,330	57,470	57,246	59,424	59,854
Current Assets	-1.5%	12,297	12,485	11,425	12,088	11,501	12,051	11,453	12,164	12,451	12,573	12,154	12,822	12,401	13,005	12,160	12,781	12,884	13,464	12,542	13,805	13,431
Cash Equivalents	-7.3%	2,991	3,226	2,249	2,670	2,176	2,801	2,225	2,091	2,250	2,165	2,045	2,436	1,743	2,177	1,827	2,402	1,804	1,975	1,241	2,165	1,973
Inventory	-1.8%	3,949	4,021	4,051	4,109	4,118	3,833	3,859	4,049	4,012	3,818	4,167	4,362	4,406	4,403	4,516	4,361	4,290	4,422	4,636	4,850	4,782
Net PPE	-2.3%	5,618	5,750	5,622	5,712	5,751	5,739	5,568	5,740	5,932	5,982	6,040	6,127	6,112	6,296	6,152	6,122	6,221	6,436	6,643	6,732	6,785
Goodwill	-1.0%	17,007	17,177	16,885	17,118	17,799	17,633	18,433	18,837	19,986	20,040	20,179	20,421	20,302	20,624	20,228	24,616	24,490	24,846	24,657	24,913	24,822
Liabilities	-0.3%	35,230	35,353	34,708	35,508	34,957	35,413	34,747	36,121	36,799	36,422	36,400	37,884	38,029	39,579	39,145	40,167	40,742	42,407	42,322	44,173	44,033
Current Liabilities	12.6%	13,792	12,247	11,394	11,843	10,411	11,469	11,534	10,996	11,613	11,027	11,825	12,691	12,089	13,164	12,103	11,751	12,322	13,674	14,107	14,452	14,028
Shareholder's Equity	0.5%	7,543	7,506	7,387	7,592	8,504	7,804	9,506	9,810	10,260	11,244	11,451	11,311	10,975	11,061	10,592	14,824	14,588	15,063	14,925	15,251	15,821
Retained Earnings	-1.0%	-13,673	-13,534	-13,995	-14,066	-13,194	-12,975	-11,673	-11,734	-11,484	-10,529	-10,370	-10,662	-10,869	-10,946	-11,096	-6,747	-6,887	-6,956	-7,066	-6,752	-6,063
Additional Paid-In Capital	0.0%	27,796	27,807	27,780	27,748	27,719	27,688	27,652	27,625	27,587	27,561	27,529	27,503	27,474	27,443	27,403	27,374	27,342	27,312	27,293	27,258	27,234
Shares Outstanding	1.2%	1,133	1,119	1,121	1,120	1,115	1,110	1,111	1,110	1,107	1,102	1,103	1,101	1,099	1,095	1,096	1,096	1,093	1,091	1,091	1,091	1,090
Minority Interest	-57.3%	265	620	582	656	751	794	751	791	916	966	984	987	975	1,035	999	972	1,057	1,091	1,134	1,128	1,089
Float	-	-	-	-	8,380	-	-	-	7,300	-	-	-	9,550	-	-	-	11,830	-	-	-	8,820	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-110.5%	-124	1,184	5.00	324	-145	973	543	123	-49.00	456	529	218	-405	331	307	273	305	538	325	-227	112
Share Based Compensation	0%	28.00	28.00	31.00	30.00	32.00	36.00	26.00	39.00	24.00	33.00	26.00	29.00	31.00	38.00	29.00	32.00	30.00	20.00	35.00	30.00	34.00
Cashflow From Investing	-52.2%	144	301	184	302	181	169	147	179	161	246	288	481	508	141	157	313	252	430	224	429	272
Cashflow From Financing	73.8%	-151	-576	-576	-55.00	-706	-711	-439	-338	2.00	-501	-1,177	-1.00	-493	-125	-1,057	-3.00	-700	-241	-1,461	-35.00	-189

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TEVA Income Statement

2024-03-31

Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Net revenues

$ 3,819

$ 3,661

Cost of sales

2,048

2,079

Gross profit

1,771

1,582

Research and development expenses

242

234

Selling and marketing expenses

608

546

General and administrative expenses

278

296

Intangible assets impairments

178

Other assets impairments, restructuring and other items

^[1]

673

110

Legal settlements and loss contingencies

106

233

Other loss (income)

(2)

Operating income (loss)

^[1]

(218)

(13)

Financial expenses, net

250

260

Income (loss) before income taxes

^[1]

(467)

(272)

Income taxes (benefit)

(52)

(19)

Share in (profits) losses of associated companies, net

Net income (loss)

(419)

(253)

Net income (loss) attributable to non-controlling interests

(280)

(33)

Net income (loss) attributable to Teva

$ (139)

$ (220)

Earnings (loss) per share attributable to ordinary shareholders:

Basic

$ (0.12)

$ (0.2)

Diluted

$ (0.12)

$ (0.2)

Weighted average number of shares (in millions):

Basic

1,123

1,115

Diluted

1,123

1,115

[1]	The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.

TEVA Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($)
$ in Millions

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 2,991

$ 3,226

Accounts receivables, net of allowance for credit losses of $98 million and $95 million as of March 31, 2024 and December 31, 2023, respectively

3,456

3,408

Inventories

3,949

4,021

Prepaid expenses

1,336

1,255

Other current assets

495

504

Assets held for sale

Total current assets

12,297

12,485

Deferred income taxes

1,960

1,812

Other non-current assets

470

Property, plant and equipment, net

5,618

5,750

Operating lease right-of-use assets, net

364

397

Identifiable intangible assets, net

5,056

5,387

Goodwill

17,007

^[1]

17,177

Total assets

42,773

43,479

Current liabilities:

Short-term debt

3,060

1,672

Sales reserves and allowances

3,594

3,535

Accounts payables

2,439

2,602

Employee-related obligations

492

611

Accrued expenses

2,784

2,771

Other current liabilities

1,161

1,044

Liabilities held for sale

262

Total current liabilities

13,792

12,247

Long-term liabilities:

Deferred income taxes

569

606

Other taxes and long-term liabilities

3,991

4,019

Senior notes and loans

16,584

18,161

Operating lease liabilities

294

320

Total long-term liabilities

21,438

23,106

Commitments and contingencies, see note 10

Total liabilities

35,230

35,353

Teva shareholders' equity:

Ordinary shares of NIS 0.10 par value per share; March 31, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,238 million shares and 1,227 million shares, respectively.

Additional paid-in capital

27,796

27,807

Accumulated deficit

(13,673)

(13,534)

Accumulated other comprehensive loss

(2,775)

(2,697)

Treasury shares as of March 31, 2024 and December 31, 2023: 106 million ordinary shares

(4,128)

Stockholders' equity attributable to Teva shareholders

7,278

7,506

Non-controlling interests

265

620

Total equity

7,543

8,126

Total liabilities and equity

$ 42,773

$ 43,479

[1]	Cumulative goodwill impairment as of March 31, 2024 and December 31, 2023 was approximately $28.3 billion.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

CEO	Mr. Richard D. Francis
WEBSITE	tevapharm.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	34004

Teva Pharmaceutical Industries Ltd Frequently Asked Questions

What is the ticker symbol for Teva Pharmaceutical Industries Ltd? What does TEVA stand for in stocks?

TEVA is the stock ticker symbol of Teva Pharmaceutical Industries Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Teva Pharmaceutical Industries Ltd (TEVA)?

As of Thu May 09 2024, market cap of Teva Pharmaceutical Industries Ltd is 18.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TEVA stock?

You can check TEVA's fair value in chart for subscribers.

What is the fair value of TEVA stock?

You can check TEVA's fair value in chart for subscribers. The fair value of Teva Pharmaceutical Industries Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Teva Pharmaceutical Industries Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TEVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Teva Pharmaceutical Industries Ltd a good stock to buy?

The fair value guage provides a quick view whether TEVA is over valued or under valued. Whether Teva Pharmaceutical Industries Ltd is cheap or expensive depends on the assumptions which impact Teva Pharmaceutical Industries Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TEVA.

What is Teva Pharmaceutical Industries Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, TEVA's PE ratio (Price to Earnings) is -36.67 and Price to Sales (PS) ratio is 1.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TEVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Teva Pharmaceutical Industries Ltd's stock?

In the past 10 years, Teva Pharmaceutical Industries Ltd has provided -0.098 (multiply by 100 for percentage) rate of return.